Summary of Vital Signs at Baseline and End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
Systolic Blood Pressure (mmHg)				
After lying down for 5 minutes				
Baseline				
n	85	84	84	
Mean (SD)	138.6 (16.75)	138.8 (16.55)	140.1 (17.82)	
Median	140.0	138.0	141.0	
Min, Max	90.0, 180.0	100.0, 178.0	100.0, 188.0	
Week 24				
n	59	27	30	
Mean (SD)	135.8 (17.30)	134.1 (16.74)	132.2 (18.18)	
Median	131.0	136.0	130.0	
Min, Max	100.0, 180.0	100.0, 173.0	101.0, 178.0	
End of treatment				
n	84	84	82	
Mean (SD)	136.7 (18.30)	135.7 (17.17)	134.0 (17.86)	
Median	134.0	134.0	130.0	
Min, Max	100.0, 180.0	100.0, 190.0	101.0, 178.0	
After standing for 1 minute				
Baseline				
n	85	84	84	

Summary of Vital Signs at Baseline and End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
Mean (SD)	135.3 (17.89)	135.6 (18.04)	137.3 (19.71)	
Median	134.0	136.0	138.0	
Min, Max	90.0, 180.0	100.0, 186.0	100.0, 194.0	
Week 24				
n	59	27	30	
Mean (SD)	133.5 (19.23)	131.0 (17.82)	130.4 (20.83)	
Median	130.0	130.0	128.0	
Min, Max	90.0, 199.0	92.0, 168.0	96.0, 198.0	
End of treatment				
n	84	84	82	
Mean (SD)	133.9 (18.68)	132.8 (17.53)	130.4 (20.37)	
Median	130.5	130.0	128.0	
Min, Max	90.0, 199.0	92.0, 180.0	90.0, 198.0	
After standing for 3 minutes				
Baseline				
n	85	84	84	
Mean (SD)	136.5 (18.77)	136.4 (18.11)	138.8 (18.75)	
Median	136.0	134.5	138.0	
Min, Max	80.0, 184.0	104.0, 182.0	100.0, 186.0	
Week 24				

Summary of Vital Signs at Baseline and End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
n	59	27	30	
Mean (SD)	134.8 (17.35)	131.0 (17.92)	129.2 (16.95)	
Median	131.0	130.0	126.0	
Min, Max	100.0, 190.0	100.0, 168.0	90.0, 172.0	
End of treatment				
n	84	83	81	
Mean (SD)	134.1 (18.01)	133.1 (17.80)	130.4 (17.77)	
Median	130.0	130.0	130.0	
Min, Max	90.0, 190.0	98.0, 200.0	88.0, 184.0	
Diastolic Blood Pressure (mmHg)				
After lying down for 5 minutes				
Baseline				
n	85	84	84	
Mean (SD)	75.7 (11.09)	76.3 (9.77)	77.2 (9.80)	
Median	76.0	76.0	78.0	
Min, Max	40.0, 99.0	57.0, 100.0	51.0, 98.0	
Week 24				
n	59	27	30	
Mean (SD)	72.9 (11.32)	76.1 (9.14)	73.9 (9.23)	
Median	74.0	76.0	74.0	

Summary of Vital Signs at Baseline and End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
Min, Max	44.0, 109.0	60.0, 90.0	60.0, 92.0	
End of treatment				
n	84	84	82	
Mean (SD)	74.5 (11.11)	74.3 (8.88)	74.1 (9.27)	
Median	76.0	74.0	74.0	
Min, Max	44.0, 109.0	45.0, 90.0	56.0, 94.0	
After standing for 1 minute				
Baseline				
n	85	84	84	
Mean (SD)	77.9 (10.63)	76.2 (10.14)	78.1 (10.77)	
Median	78.0	78.0	78.0	
Min, Max	51.0, 104.0	54.0, 98.0	56.0, 108.0	
Week 24				
n	59	27	30	
Mean (SD)	74.2 (12.89)	76.3 (10.28)	74.9 (11.00)	
Median	74.0	78.0	76.0	
Min, Max	45.0, 117.0	60.0, 98.0	50.0, 97.0	
End of treatment				
n	84	84	82	
Mean (SD)	74.9 (12.16)	75.0 (9.34)	75.9 (11.77)	

Summary of Vital Signs at Baseline and End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
Median	76.0	75.0	76.5	
Min, Max	45.0, 117.0	51.0, 98.0	48.0, 112.0	
After standing for 3 minutes				
Baseline				
n	85	84	84	
Mean (SD)	77.7 (11.00)	76.6 (10.93)	79.6 (10.19)	
Median	78.0	76.0	80.0	
Min, Max	46.0, 110.0	48.0, 108.0	51.0, 104.0	
Week 24				
n	59	27	30	
Mean (SD)	74.3 (11.38)	76.2 (10.18)	76.0 (10.63)	
Median	74.0	76.0	78.5	
Min, Max	51.0, 110.0	57.0, 98.0	50.0, 98.0	
End of treatment				
n	84	83	81	
Mean (SD)	75.0 (11.19)	74.9 (9.66)	76.8 (11.71)	
Median	74.5	74.0	78.0	
Min, Max	51.0, 110.0	57.0, 102.0	50.0, 118.0	
Pulse (beats/min)				
After lying down for 5 minutes				

Summary of Vital Signs at Baseline and End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
Baseline				
n	85	84	84	
Mean (SD)	70.4 (10.46)	68.8 (9.52)	70.1 (9.27)	
Median	70.0	68.0	68.0	
Min, Max	51.0, 100.0	50.0, 88.0	52.0, 98.0	
Week 24				
n	59	27	30	
Mean (SD)	69.1 (9.46)	68.1 (9.28)	69.3 (11.88)	
Median	68.0	68.0	68.0	
Min, Max	50.0, 92.0	52.0, 90.0	47.0, 96.0	
End of treatment				
n	84	84	82	
Mean (SD)	69.3 (9.42)	67.8 (10.55)	68.1 (11.27)	
Median	68.5	68.0	68.0	
Min, Max	50.0, 92.0	48.0, 100.0	47.0, 100.0	
After standing for 1 minute				
Baseline				
n	85	84	84	
Mean (SD)	75.5 (12.68)	73.5 (10.59)	75.0 (10.89)	
Median	76.0	72.0	72.0	

Summary of Vital Signs at Baseline and End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
Min, Max	56.0, 133.0	53.0, 100.0	56.0, 104.0	
Week 24				
n	59	27	30	
Mean (SD)	72.8 (8.98)	72.1 (9.53)	73.4 (11.93)	
Median	74.0	74.0	72.0	
Min, Max	52.0, 88.0	52.0, 88.0	54.0, 98.0	
End of treatment				
n	84	84	82	
Mean (SD)	73.5 (9.09)	73.0 (10.84)	72.6 (11.11)	
Median	74.0	73.0	71.0	
Min, Max	52.0, 96.0	51.0, 104.0	52.0, 100.0	
After standing for 3 minutes				
Baseline				
n	85	84	84	
Mean (SD)	74.6 (11.94)	72.3 (10.99)	74.0 (10.76)	
Median	74.0	70.0	72.0	
Min, Max	54.0, 134.0	51.0, 104.0	52.0, 100.0	
Week 24				
n	59	27	30	
Mean (SD)	72.8 (8.73)	70.7 (10.78)	72.4 (11.92)	

Summary of Vital Signs at Baseline and End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
Median	74.0	72.0	71.5	
Min, Max	56.0, 88.0	52.0, 96.0	54.0, 96.0	
End of treatment				
n	84	83	81	
Mean (SD)	73.4 (9.08)	71.6 (10.42)	71.8 (10.76)	
Median	74.0	72.0	70.0	
Min, Max	56.0, 98.0	52.0, 97.0	54.0, 106.0	
Treatment groups are PLANNED treatment (TRT01P). Twelve subjects in this study received a treatment other than the one they were randomised to; grouping by actual treatment (TRT01A) would give column sizes of 86, 96 and 72.
Blood pressure and pulse are measured in three positions and each position is summarised as its own series: a subject's baseline after standing for three minutes is not the baseline for their supine measurement.
End of treatment is the last observed measurement of that parameter in that position, at a planned visit after Week 0 up to and including Week 24. Unscheduled visits, the Week 26 follow-up visit and records derived by averaging or carry-forward are never selected.
n is the number of subjects contributing a measurement; N in the column header is the number of subjects in the safety analysis set.	
Source: advs, adsl (pharmaverseadam). Data cut-off: 2014-07-01. open.csr display t-vitals (post-text variant); generated from the committed ARD.